Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL97 in Advanced or Metastatic Solid Tumors
NCT04965077Phase 1Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MIL97 in solid tumor, sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoint: Treatment-Emergent Adverse Events up to 2.5 years. Started Jan 2022; status: recruiting.
02
Drugs
MIL97
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04965077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965077.